Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) Director Floyd F. Petersen sold 500 shares of Amphastar Pharmaceuticals stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $41.67, for a total transaction of $20,835.00. Following the sale, the director now owns 78,833 shares in the company, valued at approximately $3,284,971.11. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Amphastar Pharmaceuticals Trading Up 1.4 %
NASDAQ AMPH opened at $42.66 on Friday. The company has a market cap of $2.08 billion, a PE ratio of 16.53, a PEG ratio of 1.01 and a beta of 0.85. The company has a current ratio of 2.17, a quick ratio of 1.70 and a debt-to-equity ratio of 0.92. Amphastar Pharmaceuticals, Inc. has a 12 month low of $35.93 and a 12 month high of $67.66. The stock has a 50 day moving average of $43.70 and a 200-day moving average of $50.76.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported $0.81 EPS for the quarter, missing the consensus estimate of $0.84 by ($0.03). Amphastar Pharmaceuticals had a net margin of 21.34% and a return on equity of 26.95%. The company had revenue of $178.11 million during the quarter, compared to analyst estimates of $174.90 million. On average, equities research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.41 EPS for the current fiscal year.
Analysts Set New Price Targets
Shocking $16T Elon Musk Crypto Leak
From Crypto 101 Media | Ad
Reports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market.
Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account."
Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.
Click here now to get your copy.
Several brokerages have recently commented on AMPH. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, February 29th. JPMorgan Chase & Co. began coverage on Amphastar Pharmaceuticals in a research note on Tuesday, March 5th. They issued an "overweight" rating and a $60.00 price target for the company. Finally, Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, April 10th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $66.00.
View Our Latest Analysis on AMPH
Institutional Inflows and Outflows
A number of hedge funds have recently modified their holdings of the stock. Federated Hermes Inc. increased its position in shares of Amphastar Pharmaceuticals by 0.4% in the third quarter. Federated Hermes Inc. now owns 3,442,234 shares of the company's stock worth $158,308,000 after purchasing an additional 13,304 shares during the period. Vanguard Group Inc. increased its position in shares of Amphastar Pharmaceuticals by 1.7% in the fourth quarter. Vanguard Group Inc. now owns 2,815,596 shares of the company's stock worth $174,145,000 after purchasing an additional 48,203 shares during the period. TD Asset Management Inc increased its position in shares of Amphastar Pharmaceuticals by 449.0% in the fourth quarter. TD Asset Management Inc now owns 793,559 shares of the company's stock worth $49,082,000 after purchasing an additional 649,001 shares during the period. Epoch Investment Partners Inc. increased its position in shares of Amphastar Pharmaceuticals by 348.7% in the fourth quarter. Epoch Investment Partners Inc. now owns 592,530 shares of the company's stock worth $36,648,000 after purchasing an additional 460,473 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its stake in Amphastar Pharmaceuticals by 44.8% in the third quarter. Jacobs Levy Equity Management Inc. now owns 554,850 shares of the company's stock valued at $25,518,000 after buying an additional 171,642 shares in the last quarter. Institutional investors own 65.09% of the company's stock.
Amphastar Pharmaceuticals Company Profile
(
Get Free Report)
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
